Reviva to Participate in the BIO International Convention
Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in San Diego, CA.
加利福尼亚州库比蒂诺，2024年5月21日——Reviva Pharmicals Holdings, Inc.（纳斯达克股票代码：RVPH）（“Reviva” 或 “公司”）是一家开发旨在解决中枢神经系统（CNS）、炎症和心脏代谢疾病领域未得到满足的医疗需求的疗法的后期制药公司，今天宣布，Laxminarayan Bhat博士，创始人、总裁兼首席执行官 Reviva将参加2024年6月3日至6日在加利福尼亚州圣地亚哥举行的BIO国际大会的小组讨论。
| BIO International Convention |
| Panel Title: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date: Tuesday, June 4, 2024 Time: 4:15 p.m PT Location: San Diego, CA |
| BIO 国际大会 |
| 小组标题： 在神经精神药物创新方面，挑战生物技术公司的单轨思维 日期：2024 年 6 月 4 日，星期二 时间：太平洋时间下午 4:15 地点：加利福尼亚州圣地亚哥 |
To register for the convention please use the link HERE.
要注册参加大会，请使用链接 这里。
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
关于 Reviva
Reviva是一家处于后期阶段的生物制药公司，致力于为社会、患者及其家庭带来未得到满足的医疗需求和负担的疾病发现、开发和寻求将下一代疗法商业化。Reviva目前的产品线侧重于中枢神经系统（CNS）、炎症和心脏代谢疾病。Reviva的产品线目前包括两种候选药物，即brilaroxazine（RP5063）和 RP1208。两者都是内部发现的新化学实体。Reviva 已在美国、欧洲和其他几个国家获得了 brilaroxazine 和 RP1208 的物质组合专利。
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
公司联系人：
Reviva 制药控股有限公司
Laxminarayan Bhat，博士
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
投资者关系联系人：
LifeSci 顾问有限公司
布鲁斯·麦克尔
bmackle@lifesciadvisors.com
Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783
媒体联系人：
克里斯汀·波利蒂
kpoliti@lifescicomms.com
(646) 876-4783
